{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:26Z","timestamp":1761058706866},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,7,18]],"date-time":"2007-07-18T00:00:00Z","timestamp":1184716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00280-007-0543-3","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T13:02:58Z","timestamp":1184677378000},"page":"855-863","source":"Crossref","is-referenced-by-count":18,"title":["Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma"],"prefix":"10.1007","volume":"61","author":[{"given":"Delphine","family":"Rolland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Camara-Clayette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Barbarat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,18]]},"reference":[{"key":"543_CR1","first-page":"2318","volume":"6","author":"AA Adjei","year":"2000","unstructured":"Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000) Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6:2318\u20132325","journal-title":"Clin Cancer Res"},{"key":"543_CR2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"key":"543_CR3","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1074\/jbc.M003469200","volume":"275","author":"HR Ashar","year":"2000","unstructured":"Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451\u201330457","journal-title":"J Biol Chem"},{"key":"543_CR4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0301-472X(00)00672-X","volume":"29","author":"L Baseggio","year":"2001","unstructured":"Baseggio L, Bienvenu J, Charlot C, Picollet J, Felman P, Coiffier B, Salles G (2001) Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from non-Hodgkin\u2019s lymphoma patients. Exp Hematol 29:330\u2013338","journal-title":"Exp Hematol"},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1535-7163.179.3.2","volume":"3","author":"DM Beaupre","year":"2004","unstructured":"Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG (2004) R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 3:179\u2013186","journal-title":"Mol Cancer Ther"},{"key":"543_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1701046","volume":"21","author":"JY Blay","year":"1998","unstructured":"Blay JY, Sebban C, Surbiguet C, Ouach\u00e9e M, Philip I, Philip T, Biron P (1998) High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin\u2019s lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 21:51\u201354","journal-title":"Bone Marrow Transplant"},{"key":"543_CR7","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36:115\u2013127","journal-title":"Semin Hematol"},{"key":"543_CR8","doi-asserted-by":"crossref","unstructured":"Casey PJ, Solski PA, Der CJ, Buss JE (1989) p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86:8323\u20138327","DOI":"10.1073\/pnas.86.21.8323"},{"key":"543_CR9","first-page":"1966","volume":"278","author":"EH Cheng","year":"1997","unstructured":"Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Blood 278:1966\u20131968","journal-title":"Blood"},{"key":"543_CR10","doi-asserted-by":"crossref","unstructured":"Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ (1997) The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 272:10608\u201310615","DOI":"10.1074\/jbc.272.16.10608"},{"key":"543_CR11","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927\u20131932","journal-title":"Blood"},{"key":"543_CR12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oxfordjournals.annonc.a059148","volume":"6","author":"B Coiffier","year":"1995","unstructured":"Coiffier B, Hiddemann W, Stein H (1995) Mantle cell lymphoma: a therapeutic dilemma. Ann Oncol 6:208\u2013210","journal-title":"Ann Oncol"},{"key":"543_CR13","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","volume":"101","author":"J Cortes","year":"2003","unstructured":"Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O\u2019Brien S, Garcia-Manero G, Talpaz M, Kantarjian H (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101:1692\u20131697","journal-title":"Blood"},{"key":"543_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","volume":"16","author":"D Decaudin","year":"1998","unstructured":"Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, Bayle C, Carde P, Bendahmane B, Hayat M, Munck JN (1998) Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579\u2013583","journal-title":"J Clin Oncol"},{"key":"543_CR15","first-page":"5492","volume":"59","author":"W Du","year":"1999","unstructured":"Du W, Prendergast GC (1999) Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59:5492\u20135496","journal-title":"Cancer Res"},{"key":"543_CR16","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131\u2013137","journal-title":"Cancer Res"},{"key":"543_CR17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","volume":"148","author":"VA Fadok","year":"1992","unstructured":"Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henzon PM (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207\u20132216","journal-title":"J Immunol"},{"key":"543_CR18","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1016\/S0021-9258(19)47079-8","volume":"264","author":"CC Farnsworth","year":"1989","unstructured":"Farnsworth CC, Wolda SL, Gelb MH, Glomset JA (1989) Human lamin B contains a farnesylated cysteine residue. J Biol Chem 264:20422\u201320429","journal-title":"J Biol Chem"},{"key":"543_CR19","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fernandez","year":"2005","unstructured":"Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A (2005) Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364\u20136369","journal-title":"J Clin Oncol"},{"key":"543_CR20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/3327","volume":"4","author":"L Fink","year":"1998","unstructured":"Fink L, Seeger W, Ermert L, H\u00e4nze J, Stahl U, Grimminger F, Kummer W, Bohle RM (1998) Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 4:1329\u20131333","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"543_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","volume":"11","author":"JM Foran","year":"2000","unstructured":"Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, Johnson PW, Gisselbrecht C, Bradburn M, Matthews J, Lister TA (2000) Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 11(Suppl 1):117\u2013121","journal-title":"Ann Oncol"},{"key":"543_CR22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","volume":"17","author":"JM Foran","year":"1999","unstructured":"Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546\u2013553","journal-title":"J Clin Oncol"},{"key":"543_CR23","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, B\u00f6ck HP, Wandt H, Unterhalt M, Hiddemann W (2004) German low-grade lymphoma study group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group Blood 104:3064\u20133071","journal-title":"Blood"},{"key":"543_CR24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.275.5307.1750","volume":"275","author":"MH Gelb","year":"1997","unstructured":"Gelb MH (1997) Protein prenylation, et cetera: signal transduction in two dimensions. Science 275:1750\u20131751","journal-title":"Science"},{"key":"543_CR25","first-page":"1975","volume":"10","author":"R Haas","year":"1996","unstructured":"Haas R, Brittinger G, Meusers P, Murea S, Goldschmidt H, Wannenmacher M, Hunstein W (1996) Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 10:1975\u20131979","journal-title":"Leukemia"},{"key":"543_CR26","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","volume":"16","author":"W Hiddemann","year":"1998","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, W\u00f6ltjen HH, Kreuser ED, Tr\u00fcmper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R (1998) Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group. J Clin Oncol 16:1922\u20131930","journal-title":"J Clin Oncol"},{"key":"543_CR27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","volume":"98","author":"WK Hofmann","year":"2001","unstructured":"Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW, Koeffler HP (2001) Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98:787\u2013794","journal-title":"Blood"},{"key":"543_CR28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288\u20131294","journal-title":"J Clin Oncol"},{"key":"543_CR29","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1242\/jcs.115.17.3403","volume":"115","author":"D Hussein","year":"2002","unstructured":"Hussein D, Taylor SS (2002) Farnesylation of Cenp-F is required for G2\/M progression and degradation after mitosis. J Cell Sci 115:3403\u20133414","journal-title":"J Cell Sci"},{"key":"543_CR30","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World health organisation classification of tumours. Pathology and genetics of tumours of heamatopoietic and lymphoid tissues., edited by Press I. Lyon, pp 168\u2013170"},{"key":"543_CR31","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:3361\u20133369","journal-title":"Blood"},{"key":"543_CR32","first-page":"3544","volume":"7","author":"LR Kelland","year":"2001","unstructured":"Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End DW, Howes AJ, Dowsett M, Workman P, Johnston SRD (2001) Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544\u20133550","journal-title":"Clin Cancer Res"},{"key":"543_CR33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","volume":"8","author":"N Ketterer","year":"1997","unstructured":"Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, Bouafia F, Berger F, Felman P, Coiffier B (1997) Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 8:701\u2013704","journal-title":"Ann Oncol"},{"key":"543_CR34","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R (1998) Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803\u20133809","journal-title":"J Clin Oncol"},{"key":"543_CR35","doi-asserted-by":"crossref","first-page":"21155","DOI":"10.1074\/jbc.274.30.21155","volume":"274","author":"DG Kirsch","year":"1999","unstructured":"Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R KM, Lazebnik YA, Hardwick JM (1999) Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274:21155\u201321161","journal-title":"J Biol Chem"},{"key":"543_CR36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","volume":"84","author":"G Koopman","year":"1994","unstructured":"Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415\u20131420","journal-title":"Blood"},{"key":"543_CR37","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood.V99.12.4554","volume":"99","author":"C Korz","year":"2002","unstructured":"Korz C, Pscherer A, Benner A, Mertens D, Schaffner C, Leupolt E, D\u00f6hner H, Stilgenbauer S, Lichter P (2002) Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99:4554\u20134561","journal-title":"Blood"},{"key":"543_CR38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","volume":"22","author":"R Kurzrock","year":"2004","unstructured":"Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287\u20131292","journal-title":"J Clin Oncol"},{"key":"543_CR39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefr\u00e8re","year":"2002","unstructured":"Lefr\u00e8re F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, Janvier M, Sebban C, Casasnovas RO, Bouabdallah R, Dreyfus F, Verkarre V, Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B, Hermine O (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16:587\u2013593","journal-title":"Leukemia"},{"key":"543_CR40","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-06-1962","volume":"67","author":"Y Lepelletier","year":"2007","unstructured":"Lepelletier Y, Camara-Clayette V, Jin H, Hermant A, Coulon S, Dussiot M, Arcos-Fajardo M, Baude C, Canionni D, Delarue R, Brousse N, Benaroch P, Benhamou M, Ribrag V, Monteiro RC, Moura IC, Hermine O (2007) Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 67:1145\u20131154","journal-title":"Cancer Res"},{"key":"543_CR41","first-page":"8226","volume":"63","author":"N Martinez","year":"2003","unstructured":"Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M, Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 63:8226\u20138232","journal-title":"Cancer Res"},{"key":"543_CR42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"543_CR43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-4-56","volume":"4","author":"M Raponi","year":"2004","unstructured":"Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y (2004) Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4:56\u201367","journal-title":"BMC Cancer"},{"key":"543_CR44","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","volume":"88","author":"CL Rosenberg","year":"1991","unstructured":"Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, Arnold A (1991) PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638\u20139642","journal-title":"Proc Natl Acad Sci USA"},{"key":"543_CR45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185\u2013197","journal-title":"Cancer Cell"},{"key":"543_CR46","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","volume":"38","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Karakas T, J\u00e4ger E, Mezger J, von Gr\u00fcnhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS (2002) Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma. Eur J Cancer 38:1739\u20131746","journal-title":"Eur J Cancer"},{"key":"543_CR47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B (1998) Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 12:1281\u20131287","journal-title":"Leukemia"},{"key":"543_CR48","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871\u20133879","journal-title":"Blood"},{"key":"543_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1242\/jcs.107.1.61","volume":"107","author":"M Sinensky","year":"1994","unstructured":"Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M (1994) The processing pathway of prelamin A. J Cell Sci 107:61\u201367","journal-title":"J Cell Sci"},{"key":"543_CR50","doi-asserted-by":"crossref","first-page":"15356","DOI":"10.1073\/pnas.95.26.15356","volume":"95","author":"N Suzuki","year":"1998","unstructured":"Suzuki N, Urano J, Tamanoi F (1998) Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA 95:15356\u201315361","journal-title":"Proc Natl Acad Sci USA"},{"key":"543_CR51","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","volume":"13","author":"I Teodorovic","year":"1995","unstructured":"Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, Somers R, Bijnens L, Noordijk EM, Peeters CD (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes. European organization for the research and treatment of cancer lymphoma cooperative group. J Clin Oncol 13:2819\u20132826","journal-title":"J Clin Oncol"},{"key":"543_CR52","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2003-06-2160","volume":"103","author":"C Thieblemont","year":"2004","unstructured":"Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, Loriod B, Granjeaud S, Gaulard P, Haioun C, Traverse-Glehen A, Baseggio L, Bertucci F, Birnbaum D, Magrangeas F, Minvielle S, Avet-Loiseau H, Salles G, Coiffier B, Berger F, Houlgatte R (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103:2727\u20132737","journal-title":"Blood"},{"key":"543_CR53","doi-asserted-by":"crossref","unstructured":"Vandenberghe E, De Wolf-Peeters C, van den Oord J, Wlodarska I, Delabie J, Stul M, Thomas J, Michaux JL, Mecucci C, JJ C (1991) Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 163:13\u201318","DOI":"10.1002\/path.1711630104"},{"key":"543_CR54","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood.V108.11.530.530","volume":"108","author":"TE Witzig","year":"2006","unstructured":"Witzig TE, Maurer MJ, Johnston PB, Colgan JP, Kaufmann SH, Inwards DJ, Micallef IN, Ansell SM, Zent CS, Allmer C, Weiner GJ, Wooldridge JE, Link BK, Habermann TM (2006) Oral tipifarnib (R115777) has single agent anti-tumor activity in patients with relapsed aggressive non-Hodgkin lymphoma (NHL): results of a phase II trial in the University of Iowa\/Mayo clinic lymphoma SPORE (CA97274) [ASH annual meeting abstract]. Blood 108:530","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0543-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0543-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0543-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T11:49:21Z","timestamp":1683978561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0543-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,18]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0543-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,18]]}}}